Both glucagon-like peptide 1 (GLP-1) agonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors are important drugs in our armamentarium of treatment for Type 2 diabetes mellitus (DM) and obesity. Here, SLC5A2 is linked to type 2 diabetes mellitus.